Exelixis, Inc. $EXEL Shares Sold by Krilogy Financial LLC

Krilogy Financial LLC decreased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 31.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,111 shares of the biotechnology company’s stock after selling 9,791 shares during the period. Krilogy Financial LLC’s holdings in Exelixis were worth $937,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Exelixis by 11.2% during the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock worth $172,658,000 after acquiring an additional 419,596 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Exelixis by 62.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 187,154 shares of the biotechnology company’s stock valued at $8,224,000 after acquiring an additional 71,987 shares during the last quarter. Elo Mutual Pension Insurance Co lifted its holdings in Exelixis by 124.3% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 54,643 shares of the biotechnology company’s stock valued at $2,257,000 after acquiring an additional 30,279 shares during the last quarter. Private Client Services LLC bought a new position in shares of Exelixis during the 4th quarter valued at about $1,992,000. Finally, Stephens Investment Management Group LLC boosted its position in shares of Exelixis by 1.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 2,539,421 shares of the biotechnology company’s stock valued at $111,303,000 after purchasing an additional 28,265 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on EXEL. Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Citizens Jmp upped their price target on Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Wednesday. Barclays increased their price objective on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research report on Monday, April 20th. Finally, HC Wainwright raised their price objective on Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $46.87.

Insider Activity at Exelixis

In other news, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the transaction, the chief financial officer directly owned 952,317 shares in the company, valued at $47,615,850. The trade was a 3.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 219,170 shares of company stock worth $10,620,641. Insiders own 2.60% of the company’s stock.

Exelixis Price Performance

Shares of EXEL opened at $54.77 on Friday. Exelixis, Inc. has a one year low of $33.76 and a one year high of $55.15. The company has a 50-day moving average of $49.59 and a two-hundred day moving average of $45.50. The stock has a market cap of $13.77 billion, a price-to-earnings ratio of 18.20, a PEG ratio of 1.53 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 earnings per share. Analysts anticipate that Exelixis, Inc. will post 3.16 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.